Robin E. Offord
Affiliations: | 1962-1965 | University of Cambridge, Cambridge, England, United Kingdom | |
| 1966-1980 | University of Oxford, Oxford, United Kingdom | ||
| 1980-2003 | Université de Genève, Genève, Genève, Switzerland |
Website:
http://www.americanpeptidesociety.org/pages/bio.asp?id=73Google:
"Robin E. Offord"Mean distance: (not calculated yet)
Children
Sign in to add trainee| Carmichael J.A. Wallace | grad student | 1976 | Oxford |
| Amos Bairoch | grad student | 1984-1989 | (Computational Biology Tree) |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| McBride JW, Malcolm RK, Dias N, et al. (2019) Development and pharmacokinetics of a combination vaginal ring for sustained release of dapivirine and the protein microbicide 5P12-RANTES. International Journal of Pharmaceutics. 564: 207-213 |
| McBride JW, Boyd P, Dias N, et al. (2019) Vaginal rings with exposed cores for sustained delivery of the HIV CCR5 inhibitor 5P12-RANTES. Journal of Controlled Release : Official Journal of the Controlled Release Society. 298: 1-11 |
| Cerini F, Offord RE, McGowan I, et al. (2017) Stability of 5P12-RANTES, a candidate rectal microbicide, in human rectal lavage. Aids Research and Human Retroviruses |
| Cerini F, Gaertner H, Madden K, et al. (2015) A scalable low-cost cGMP process for clinical grade production of the HIV inhibitor 5P12-RANTES in Pichia pastoris. Protein Expression and Purification |
| Choi WT, Nedellec R, Coetzer M, et al. (2012) CCR5 mutations distinguish N-terminal modifications of RANTES (CCL5) with agonist versus antagonist activity. Journal of Virology. 86: 10218-20 |
| Pilch-Cooper HA, Sieg SF, Hope TJ, et al. (2011) Circulating human CD4 and CD8 T cells do not have large intracellular pools of CCR5. Blood. 118: 1015-9 |
| Nedellec R, Coetzer M, Lederman MM, et al. (2010) "Resistance" to PSC-RANTES revisited: two mutations in human immunodeficiency virus type 1 HIV-1 SF162 or simian-human immunodeficiency virus SHIV SF162-p3 do not confer resistance. Journal of Virology. 84: 5842-5 |
| Veazey RS, Ling B, Green LC, et al. (2009) Topically applied recombinant chemokine analogues fully protect macaques from vaginal simian-human immunodeficiency virus challenge. The Journal of Infectious Diseases. 199: 1525-7 |
| Gaertner HF, Cerini F, Escola J, et al. (2008) Highly potent, fully recombinant anti-HIV chemokines: reengineering a low-cost microbicide. Proceedings of the National Academy of Sciences of the United States of America. 105: 17706-17711 |
| Cerini F, Landay A, Gichinga C, et al. (2008) Chemokine analogues show suitable stability for development as microbicides. Journal of Acquired Immune Deficiency Syndromes (1999). 49: 472-6 |